Trial Profile
Phase I Study of TTI-101, an Oral Inhibitor of Signal Transducer and Activator of Transcription (STAT) 3, in Patients With Advanced Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2024
Price :
$35
*
At a glance
- Drugs TTI 101 (Primary)
- Indications Gastric cancer; Liver cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors StemMed; Tvardi Therapeutics
- 08 Apr 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
- 08 Apr 2024 Planned primary completion date changed from 1 Mar 2024 to 1 Dec 2024.
- 20 Nov 2023 Planned End Date changed from 1 Oct 2023 to 1 Jun 2024.